Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cochlear ( (AU:COH) ) has issued an announcement.
Cochlear Limited reported a 4% increase in sales revenue for FY25, reaching $2,356 million, driven by strong growth in cochlear and acoustic implant sales, although services revenue declined. A significant highlight was the launch of the Cochlear Nucleus Nexa System, the first smart cochlear implant with upgradeable firmware, which is expected to drive revenue growth in developed markets. Despite a modest loss in market share due to regulatory delays, the company maintained a global market share above 60%. The adults and seniors segment saw strong growth, while the children’s segment experienced a slight decline. Emerging markets showed over 20% unit growth, with a surge in the second half of the year. Services revenue faced challenges due to high satisfaction with existing products and cost-of-living pressures in the US. Acoustics revenue grew by 8%, supported by the Cochlear Osia Implant’s success and expansion into new markets.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
More about Cochlear
Cochlear Limited operates in the medical device industry, specializing in the development and distribution of cochlear and acoustic implants. The company focuses on providing hearing solutions that improve health outcomes, educational cost savings, and productivity gains for individuals with hearing impairments.
Average Trading Volume: 173,116
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$20.4B
Learn more about COH stock on TipRanks’ Stock Analysis page.